These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 29138547

  • 1. Efficacy of tiotropium and indacaterol monotherapy and their combination on dynamic lung hyperinflation in COPD: a random open-label crossover study.
    Fujimoto K, Yamazaki H, Ura M, Kitaguchi Y.
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3195-3201. PubMed ID: 29138547
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of tiotropium and olodaterol combination therapy on dynamic lung hyperinflation evaluated by hyperventilation in COPD: an open-label, comparative before and after treatment study.
    Kawachi S, Fujimoto K.
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1167-1176. PubMed ID: 31213796
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.
    Vogelmeier CF, Gaga M, Aalamian-Mattheis M, Greulich T, Marin JM, Castellani W, Ninane V, Lane S, Nunez X, Patalano F, Clemens A, Kostikas K, CRYSTAL study investigators.
    Respir Res; 2017 Jul 18; 18(1):140. PubMed ID: 28720132
    [Abstract] [Full Text] [Related]

  • 8. Relieving exertional dyspnea during the 3-min constant speed shuttle test in patients with COPD with indacaterol/glycopyrronium versus tiotropium: the RED trial.
    Beaulieu J, Jensen D, O'Donnell DE, Brouillard C, Tracey L, Vincent S, Nadreau É, Bernard E, Bernard S, Maltais F.
    Ther Adv Respir Dis; 2020 Jul 18; 14():1753466620939507. PubMed ID: 32663102
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
    Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P.
    Int J Chron Obstruct Pulmon Dis; 2014 Jul 18; 9():215-28. PubMed ID: 24596459
    [Abstract] [Full Text] [Related]

  • 10. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.
    Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R.
    Int J Chron Obstruct Pulmon Dis; 2017 Jul 18; 12():1325-1337. PubMed ID: 28496316
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.
    Chan MC, Tan EC, Yang MC.
    Int J Chron Obstruct Pulmon Dis; 2018 Jul 18; 13():1079-1088. PubMed ID: 29670344
    [Abstract] [Full Text] [Related]

  • 12. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
    Ulrik CS.
    Int J Chron Obstruct Pulmon Dis; 2014 Jul 18; 9():331-8. PubMed ID: 24729699
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study.
    Hashimoto S, Ikeuchi H, Murata S, Kitawaki T, Ikeda K, Banerji D.
    Int J Chron Obstruct Pulmon Dis; 2016 Jul 18; 11():2543-2551. PubMed ID: 27785010
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferences.
    Ohno T, Wada S, Hanada S, Sawaguchi H, Muraki M, Tohda Y.
    Int J Chron Obstruct Pulmon Dis; 2014 Jul 18; 9():107-14. PubMed ID: 24489464
    [Abstract] [Full Text] [Related]

  • 16. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
    Hohlfeld JM, Vogel-Claussen J, Biller H, Berliner D, Berschneider K, Tillmann HC, Hiltl S, Bauersachs J, Welte T.
    Lancet Respir Med; 2018 May 18; 6(5):368-378. PubMed ID: 29477448
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
    Dahl R, Jadayel D, Alagappan VK, Chen H, Banerji D.
    Int J Chron Obstruct Pulmon Dis; 2013 May 18; 8():501-8. PubMed ID: 24159259
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review.
    Jiang FM, Liang ZA, Zheng QL, Wang RC, Luo J, Li CT.
    Lung; 2013 Apr 18; 191(2):135-46. PubMed ID: 23306410
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.